Ep300/CREBBP-IN-8 structure
|
Common Name | Ep300/CREBBP-IN-8 | ||
---|---|---|---|---|
CAS Number | 2259641-24-0 | Molecular Weight | 483.51 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C25H27F2N5O3 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Ep300/CREBBP-IN-8Ep300/CREBBP-IN-8 (Example 37) is a potent and orally active Ep300 and CREBBP inhibitor with IC50s of 0.014 and 0.018 μM, respectively. Ep300/CREBBP-IN-8 can be used for the research of cancer[1]. |
Name | Ep300/CREBBP-IN-8 |
---|
Description | Ep300/CREBBP-IN-8 (Example 37) is a potent and orally active Ep300 and CREBBP inhibitor with IC50s of 0.014 and 0.018 μM, respectively. Ep300/CREBBP-IN-8 can be used for the research of cancer[1]. |
---|---|
Related Catalog | |
Target |
EP300:0.014 μM (IC50) CREBBP:0.018 μM (IC50) |
In Vitro | Ep300/CREBBP-IN-8 (Example 37) 抑制细胞内 H3K27Ac 活性,其 IC50 为 0.016 μM[1]。 Ep300/CREBBP-IN-8 (38 nM-10 mM; 3 days) 抑制 LK2 和 TE-8 细胞生长,GI50 分别为 85.917 μM 和 112.922 μM [1]。 Cell Viability Assay[1] Cell Line: LK2 and TE-8 cells Concentration: 38 nM-10 mM Incubation Time: 3 days Result: Inhibited LK2 and TE-8 cell growth with GI50s of 85.917 and 112.922 μM, respectively. |
In Vivo | Ep300/CREBBP-IN-8 (Example 37; 6.25 mg/kg/day; oral; twice daily for 11 days) 抑制小鼠肿瘤增殖[1]。 Animal Model: Female BALB/c-nu/nu mice, LK2 cell subcutaneous transplant model[1] Dosage: 6.25 mg/kg/day Administration: Oral administration, twice a day for 11 days Result: Inhibited tumor volume by 42%. |
References |
[1]. NAITO Hiroyuki, et al. EP300 / CREBBP inhibitor. Patent JPWO2018235966A1. |
Molecular Formula | C25H27F2N5O3 |
---|---|
Molecular Weight | 483.51 |